Advancements With CGM Integrations: Insulin Pumps, Connected Pens, and Ketone Monitoring

This activity was originally presented during the 2025 PTCE Diabetes Day of Education on May 29, 2025.

This activity includes patient counseling video vignettes.

Program Description
Early detection and treatment of diabetes-related complications can help to reduce the overall cost of health care and burden for people living with diabetes. Complications may arise when individuals living with diabetes have high glucose levels or high levels of ketones, which can be a sign of diabetic ketoacidosis (DKA). This session will highlight recent advancements with the integration of continuous glucose monitoring with insulin pumps for automated insulin delivery systems, connected insulin pens, as well as the investigational use of continuous ketone monitoring, and the benefits of these technologies in minimizing diabetes-related complications. This session features patient counseling videos that illustrate the practical application of these integrated systems and tips to share with people living with diabetes.

Target Audience: Community pharmacists and pharmacy technicians

Type of Activity: Application
Release date: June 4, 2025
Expiration date: June 4, 2026
Learner level: Foundational
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Differentiate the benefits, limitations, and potential challenges associated with using continuous glucose monitoring (CGM) devices and automated insulin delivery (AID) systems
• Customize a personalized diabetes management plan that incorporates the use of a CGM device and AID system, as appropriate
• Identify people living with diabetes who may benefit from ketone monitoring and progress with continuous ketone monitoring

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity numbers 0290-0000-25-177-H01-P and 0290-0000-25-177-H01-T. The activity is available for CE credit through June 4, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Davida F. Kruger, MSN, APN-BC,BC-ADM, has the following relevant financial relationships with commercial interests to disclose:

Consultant: Abbott, CeQur, Lilly, Mannkind, Medtronic, Sequel, Corcept, Arcor, Structure
Speakers Bureau:Dexcom, CeQur, Lilly, Novo, Abbott, Insulet, Tandem
Grant/Research Support: Abbott, Insulet, Sequel, Tandem
Stock: Pendulum

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Heather P. Whitley, PharmD, BCPS, CDCES, FCCP

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Liza Patel, PharmD, RPh; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms